BiotechTube

AD04 (ondansetron) + Matching placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Use Disorder

Conditions

Alcohol Use Disorder

Trial Timeline

Feb 1, 2020 → Mar 18, 2022

NCT ID
NCT04101227

About AD04 (ondansetron) + Matching placebo

AD04 (ondansetron) + Matching placebo is a phase 3 stage product being developed by Adial Pharmaceuticals for Alcohol Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04101227. Target conditions include Alcohol Use Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04101227Phase 3Completed

Competing Products

20 competing products in Alcohol Use Disorder

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
LY686017 + PlaceboEli LillyPhase 2
52
LY3537031 + PlaceboEli LillyPhase 3
77
GODEX + PlaceboCelltrionPhase 3
77
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
ASP8062 + PlaceboAstellas PharmaPhase 2
52
LY686017 + PlaceboEli LillyPhase 2
52
Mazdutide + PlaceboEli LillyPhase 2
52
opioid receptor kappa antagonistEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
LY2196044 + placeboEli LillyPhase 2
52
LY3537031 + PlaceboEli LillyPhase 3
77